Photodynamic therapy is an important component in the treatment of AKs. Herein, our pilot study hopes to shed light on the great rate of clearance in the number of AKs with the use of only 308-nm blue light without any photosensitizing agents. We propose that in patients with known contraindications to photosensitizing agents, this could be an effective way to clear AKs while avoiding the harmful side effects of photosensitizing agents. It would be beneficial to conduct a split study comparing the effects of using photosensitizing agent on one side while exposing only to blue light on the other side. This would allow for the observation of the difference in reduction of AKs on both sides.
DISCLOSURES
The authors have no conflicts of interest to declare.
REFERENCES
1. Abrahamse H, Hamblin MR. New photosensitizers for photodynamic therapy. Biochem J. 2016;473(4):347-64. doi: 10.1042/BJ20150942.
2. Foley P, Freeman M, Menter A, et al. Photodynamic therapy with methyl aminolevulinate for primary nodular basal cell carcinoma: results of two randomized studies. Int J Dermatol. 2009;48(11):1236-45. doi: 10.1111/j.1365- 4632.2008.04022.x.
3. Wang H, Xu Y, Shi J, Gao X, et al. Photodynamic therapy in the treatment of basal cell carcinoma: a systematic review and meta-analysis. Photodermatol Photoimmunol Photomed. 2015;31(1):44-53. doi: 10.1111/phpp.12148.
4. Lim HW. Shedding light on photodynamic therapy for basal cell carcinoma. Br J Dermatol. 2018;179(6):1240-1241. doi: 10.1111/bjd.17187.
5. Using Blu-U®. DUSA: a SUN PHARMA company. Available at: https://www. levulanhcp.com/blu-u.html. Accessed August 1, 2022.
6. Vergilis-Kalner IJ, Tsoukas M. Treatment of actinic keratoses and superficial non-melanotic skin cancers with photodynamic therapy with 5-aminominolevulinic acid versus conventional therapies. 2007; American Society for Dermatologic Surgery Annual Meeting.
7. Kwiatkowski S, Knap B, Przystupski D, et al. Photodynamic therapy - mechanisms, photosensitizers and combinations. Biomed Pharmacother. 2018;106:1098-1107. doi: 10.1016/j.biopha.2018.07.049.
2. Foley P, Freeman M, Menter A, et al. Photodynamic therapy with methyl aminolevulinate for primary nodular basal cell carcinoma: results of two randomized studies. Int J Dermatol. 2009;48(11):1236-45. doi: 10.1111/j.1365- 4632.2008.04022.x.
3. Wang H, Xu Y, Shi J, Gao X, et al. Photodynamic therapy in the treatment of basal cell carcinoma: a systematic review and meta-analysis. Photodermatol Photoimmunol Photomed. 2015;31(1):44-53. doi: 10.1111/phpp.12148.
4. Lim HW. Shedding light on photodynamic therapy for basal cell carcinoma. Br J Dermatol. 2018;179(6):1240-1241. doi: 10.1111/bjd.17187.
5. Using Blu-U®. DUSA: a SUN PHARMA company. Available at: https://www. levulanhcp.com/blu-u.html. Accessed August 1, 2022.
6. Vergilis-Kalner IJ, Tsoukas M. Treatment of actinic keratoses and superficial non-melanotic skin cancers with photodynamic therapy with 5-aminominolevulinic acid versus conventional therapies. 2007; American Society for Dermatologic Surgery Annual Meeting.
7. Kwiatkowski S, Knap B, Przystupski D, et al. Photodynamic therapy - mechanisms, photosensitizers and combinations. Biomed Pharmacother. 2018;106:1098-1107. doi: 10.1016/j.biopha.2018.07.049.
AUTHOR CORRESPONDENCE
Samantha Kalner samantha.kalner@gmail.com
